Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Yulianti M., Johan C., Singh G., Tenda E.D., Herikurniawan H., Wijaya I.P.E.K.
57216405885;57428554200;57209127773;57189692101;57428567200;57221504958;
Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report
2021
Acta medica Indonesiana
53
4
497
504
Department of Internal Medicine, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia
Yulianti, M., Department of Internal Medicine, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Johan, C.; Singh, G.; Tenda, E.D.; Herikurniawan, H.; Wijaya, I.P.E.K.
BACKGROUND: Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in COVID-19 patients compared to standard medical therapy. METHODS: We conducted a search of Pubmed, Cochrane, and EBSCO for studies assessing the clinical question using inclusion and exclusion criteria. Selected studies were critically appraised, and the results were summarized. RESULTS: A meta-analysis of 10 randomized clinical trials (RCTs), an RCT, a case-control clinical study were selected and assessed. Only the case-control clinical study showed that convalescent plasma administration improved the clinical outcomes of patients with COVID-19, including all-cause mortality, hospital length of stay, and the need for mechanical ventilation. On the contrary, the other two studies of a higher level of evidence showed no significant clinical outcome improvement with convalescent plasma therapy. CONCLUSION: The effectiveness of convalescent plasma therapy in improving clinical outcomes of patients with COVID-19 was still inconclusive due to several study limitations and other possible causes.
convalescent plasma; coronavirus; COVID-19; SARS-CoV-2
artificial ventilation; human; meta analysis; passive immunization; randomized controlled trial (topic); therapy; treatment outcome; COVID-19; Humans; Immunization, Passive; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Treatment Outcome
NLM (Medline)
01259326
35027500
Article
Q3
321
14162